Klinische Erfahrungen mit Ribonucleinsäuren bei myogenen und neuromuskulären Erkrankungen

Journal/Book: Erfahrungsheilkunde. 1989; 38/12: 848-853.

Abstract: The myopen and neuromuscular diseases still are considerable therapeutic problems, for example the hereditary muscular dystrophies, spinal and neuronal muscular atrophies.As there is no causal therapy, they are until today incurable and only symptomatic measures are available.The only therapeutic approach is the prevention or at least retardation of progression, in order to keep up the quality of life as long as possible, expectating effective and sure therapeutic treatments.RNA and their synthesis should be of great interest since the reduction of muscular protiens is of great pathogenetic significance, either in muscular dystrophies (= md) as in spinal muscular atrophies (= sma). The course of neuro-sma shows also myopathic changes caused by metabolic disorders of proteins, secondary after an atrophic phase. Biochemical examinations have proved that the mechanisms of reparation in the organism and the normal metabolism of proteins are RNA-dependent syntheses.We will describe experiences and observations of the course of muscular dystrophy and atrophy during a pilot study with RNA-treated children and adults. For the selection of RNA types their organic specifity-rather than their specifity of sort-had to be considered. RNA from thymus, lymphatic nodes, pituitary, basal ganglia and midstem brain an the basis of tissue of muscles and medulla spinals were applied.As long as there is no causal therapy of these diseases available, RNA can be therapeutically useful, as our experiences show. RNA have no side effects and are well tolerated. We recommend to verify these experiences, especially by randomised studies.

Zurück | Weiter